

PUBLIC SUMMARY DOCUMENT

Product: Moderma Flex Urostomy Flat CTF

Applicant: Hollister

Date of SPAP Meeting: 11 April 2016

1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Hollister, sought listing of the Moderma Flex Urostomy Flat CTF, in sub-group 3(a) of the Stoma Appliance Scheme (SAS) Schedule. The product, including two variants, was proposed for listing at the benchmark unit price of \$4.674, with a maximum monthly quantity of 60 units.

2. Comparator

The applicant nominated Moderma Flex Urostomy Pouch (SAS code 9801W) from its own range, which is currently listed in subgroup 3(a), as the comparator. This product is currently listed at the unit price of \$4.674 and a monthly maximum quantity of 60 units.

3. Background

This was the Stoma Product Assessment Panel (SPAP)'s first consideration of this product.

4. Clinical Place for the Product

The proposed product provides an alternative for users requiring a one-piece urostomy pouch with flat baseplate and a cut-to-fit opening. The product is a direct substitute for the comparator currently available in subgroup 3(a).

5. SPAP Comment

Clinical Analysis

The Panel noted that the proposed product is claimed to be an upgraded version of the Moderma Flex Urostomy Pouch (SAS code 9801W) and is stated to include a curved pouch design, multiple built-in-chambers to evenly distribute urine resulting in lower profile chamber, new valve/drain tap control function and new drainage adapter for easier connection to the pouch.

Economic Analysis

Not undertaken.

Financial Analysis

Listing of this product would be on a cost-minimisation basis compared with the nominated comparator product in subgroup 3(a) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product under the conditions requested by the applicant.

6. SPAP Recommendation

The SPAP recommended that the Moderma Flex Urostomy Flat CTF, including two variants, be listed in subgroup 3(a) of the SAS Schedule at the benchmark unit price \$4.674, with a maximum monthly quantity of 60 units.

7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is

an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

8. Applicant's Comment

Hollister agrees with SPAP's recommendation.